Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial-Reference-Cited by-同舟云学术

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

Published:2015-11 Issue:15 Volume:16 Page:1515-1524
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Symonds R Paul,Gourley Charlie,Davidson Susan,Carty Karen,McCartney Elaine,Rai Debbie,Banerjee Susana,Jackson David,Lord Rosemary,McCormack Mary,Hudson Emma,Reed Nicholas,Flubacher Maxine,Jankowska Petra,Powell Melanie,Dive Caroline,West Catharine M L,Paul James

Funder

Cancer Research UK

NHS Greater Glasgow & Clyde and University of Glasgow

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBO CAN 2012;Ferlay;Int J Cancer,2015

2. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study;Monk;J Clin Oncol,2009

3. High tumour angiogenesis is associated with poorer survival in carcinoma of the cervix treated by radiotherapy;Cooper;Clin Cancer Res,1998

4. Tumour vascularity is a significant prognostic factor for cervix cancer treated by radiotherapy: independence from tumour radiosensitivity;Cooper;Br J Cancer,1999

5. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of cervix;Loncaster;Br J Cancer,2000

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future;Expert Opinion on Drug Metabolism & Toxicology;2024-09-09

2. A Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with extensive-stage small-cell lung cancer or metastatic neuroendocrine non-small-cell lung cancer;Clinical Lung Cancer;2024-09

3. Pharmacotherapy for cervical cancer: current standard of care and new perspectives;Expert Opinion on Pharmacotherapy;2024-08-12

4. Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer;Medical Oncology;2024-07-10

5. New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects;Cancer Investigation;2024-07-05